COVID-19: Updated Data and its Relation to the Cardiovascular System

Area of Science:

• Cardiology
• Infectious Diseases
• Public Health

Background:

• The emergence of SARS-CoV-2 has led to a global pandemic (COVID-19).
• COVID-19 presents with respiratory symptoms and is associated with cardiac complications.
• Patients with pre-existing cardiovascular conditions or on specific medications may face increased risks.

Purpose of the Study:

• To explore the relationship between COVID-19 and cardiovascular health.
• To investigate the potential impact of ACE inhibitors and ARBs on COVID-19 progression.
• To inform healthcare professionals about managing COVID-19 in cardiac patients.

Main Methods:

• Literature review and synthesis of current evidence regarding COVID-19 and cardiovascular disease.
• Analysis of the role of ACE2 receptors in viral entry.
• Discussion of clinical implications for patients with hypertension and diabetes.

Main Results:

• A significant number of hospitalized COVID-19 patients have cardiovascular or cerebrovascular diseases.
• Systemic inflammation and immune dysregulation may link COVID-19 to cardiac damage.
• No current evidence supports discontinuing ACE inhibitors or ARBs due to COVID-19 risk.

Conclusions:

• COVID-19 can exacerbate underlying cardiovascular conditions.
• The use of ACE inhibitors and ARBs requires careful consideration of risks and benefits in the context of COVID-19.
• Cardiologists and healthcare providers must remain vigilant and protect themselves during the pandemic.